Continuous glucose monitoring in peritoneal dialysis: What the evidence supports and where it stops

Glycaemic assessment is particularly difficult in people treated with peritoneal dialysis (PD). Glycated haemoglobin loses accuracy and precision in advanced kidney disease, and continuous absorption of dialysate glucose creates a glycaemic load that intermittent capillary testing cannot capture. Continuous glucose monitoring (CGM) provides dense ambulatory interstitial glucose data, but PD-specific evidence remains small and heterogeneous. In the largest CGM cohort of people receiving maintenance dialysis, hyperglycaemia that was often not clinically evident was most prominent among those treated with PD. This narrative review appraises the analytical performance, clinical accuracy and practical limitations of CGM in PD and separates defensible conclusions from over-interpretation. Contemporary sensors have shown acceptable accuracy against laboratory references in small single-centre PD cohorts, including one of icodextrin-treated patients, but performance varies with device, calibration requirement, reference standard and dialysis modality, and both the magnitude and the direction of sensor error affect time-in-range metrics. The best-documented icodextrin hazard is maltose interference with non-glucose-specific blood glucose meters used for confirmation or calibration. Because glucose specificity is a property of each enzyme and sensor, and anuric patients receiving daily icodextrin have not been specifically studied, device-specific validation in this subgroup remains a safety prerequisite before sensor readings guide insulin dosing. CGM is a reasonable adjunct for selected patients, particularly when laboratory markers are discordant, but current data do not support prescriptive treatment algorithms or regulatory conclusions. Pragmatic multicentre accuracy studies, registries and trials using CGM-derived and patient-reported outcomes are realistic next steps.

Authors

Institutions

Publication Details

Journal
Peritoneal Dialysis International
Published
2026-11-21
DOI
https://doi.org/10.1177/08968608261508817
Primary Topic
Dialysis and Renal Disease Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Continuous glucose monitoring in peritoneal dialysis: What the evidence supports and where it stops

Gerry George Mathew
Peritoneal Dialysis International
Dialysis and Renal Disease Management
article

Continuous glucose monitoring in peritoneal dialysis: What the evidence supports and where it stops

Gerry George Mathew
article en

Abstract

Glycaemic assessment is particularly difficult in people treated with peritoneal dialysis (PD). Glycated haemoglobin loses accuracy and precision in advanced kidney disease, and continuous absorption of dialysate glucose creates a glycaemic load that intermittent capillary testing cannot capture. Continuous glucose monitoring (CGM) provides dense ambulatory interstitial glucose data, but PD-specific evidence remains small and heterogeneous. In the largest CGM cohort of people receiving maintenance dialysis, hyperglycaemia that was often not clinically evident was most prominent among those treated with PD. This narrative review appraises the analytical performance, clinical accuracy and practical limitations of CGM in PD and separates defensible conclusions from over-interpretation. Contemporary sensors have shown acceptable accuracy against laboratory references in small single-centre PD cohorts, including one of icodextrin-treated patients, but performance varies with device, calibration requirement, reference standard and dialysis modality, and both the magnitude and the direction of sensor error affect time-in-range metrics. The best-documented icodextrin hazard is maltose interference with non-glucose-specific blood glucose meters used for confirmation or calibration. Because glucose specificity is a property of each enzyme and sensor, and anuric patients receiving daily icodextrin have not been specifically studied, device-specific validation in this subgroup remains a safety prerequisite before sensor readings guide insulin dosing. CGM is a reasonable adjunct for selected patients, particularly when laboratory markers are discordant, but current data do not support prescriptive treatment algorithms or regulatory conclusions. Pragmatic multicentre accuracy studies, registries and trials using CGM-derived and patient-reported outcomes are realistic next steps.

Peritoneal Dialysis International
SRM Institute of Science and Technology (IN)
Dialysis and Renal Disease Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Continuous glucose monitoring in peritoneal dialysis: What the evidence supports and where it stops — Gerry George Mathew · Peritoneal Dialysis International (2026) | TGRS Research Map | TGRS